SCHEMBL1279290

SCHEMBL1279290

COC(=O)CNCc1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A4 P14672 1/20 0.51
EGFR P00533 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
PKM P14618 1/20 0.50
ALOX15 P16050 1/20 0.50
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
BLM P54132 1/20 0.49
PMP22 Q01453 1/20 0.49
SPR P35270 1/20 0.48
HTR2A P28223 2/20 0.47
HTR2C P28335 1/20 0.47
HSP90AB1 P08238 1/20 0.46
MEN1 O00255 1/20 0.46
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11953351 0.83 HDAC1 (0.54) CYP1A2CYP3A4KMT2ALMNAMAPT
SCHEMBL9446003 0.83 KDM4E (0.54) CYP1A2CYP3A4KMT2AKDM4ELMNA
SCHEMBL13194411 0.83 MEN1 (0.44) KMT2AKDM4EMEN1MEP1B
SCHEMBL16702357 0.83 MEN1 (0.48) KMT2AHTR2AMEN1
SCHEMBL3912954 0.83 MEN1 (0.44) KMT2AKDM4EMEN1MEP1B
SCHEMBL12276187 0.81 SLC2A4 (0.56) SLC2A4CYP1A2CYP3A4PKMALOX15
SCHEMBL19401273 0.81 MEN1 (0.50) KMT2AKDM4ELMNAMAPTMEN1
SCHEMBL717052 0.81 MEN1 (0.50) KMT2AKDM4ELMNAMAPTMEN1
SCHEMBL30435086 0.80 HSP90AB1 (0.67) EGFRCYP1A2CYP3A4PKMALOX15
SCHEMBL979023 0.80 HSP90AB1 (0.67) EGFRCYP1A2CYP3A4PKMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104130247-B Human T 2 R bitterness receptors and application thereof 塞诺米克斯公司 2018-06-01 CN disclosed
US-20160376263-A1 BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF SENOMYX INC (US) 2016-12-29 US disclosed
US-20160376263-A1 BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF SENOMYX INC (US) 2016-12-29 US disclosed
US-9247759-B2 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2016-02-02 US disclosed
US-9247759-B2 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2016-02-02 US disclosed
US-9247759-B2 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2016-02-02 US disclosed
EP-2044040-B1 1,3-OXAZOLE DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS BRISTOL MYERS SQUIBB CO (US) 2015-10-21 EP disclosed
EP-2487169-B1 Compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX INC (US) 2015-05-20 EP disclosed
EP-2487169-B1 Compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX INC (US) 2015-05-20 EP disclosed
CN-104130247-A Human T2R bitter taste receptors and the use thereof SENOMYX INC 2014-11-05 CN disclosed
US-20100254916-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof SENOMYX, INC. (US) 2010-10-07 US disclosed
US-7795291-B2 Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-14 US disclosed
CN-101828111-A Human T2R bitter taste receptor and uses thereof SENOMYX INC 2010-09-08 CN disclosed
EP-2195656-A2 HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF Senomyx, Inc. (US) 2010-06-16 EP disclosed
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2009-11-05 US disclosed
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2009-11-05 US disclosed
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof SENOMYX, INC. (US) 2009-11-05 US disclosed
WO-2009025793-A2 HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF SENOMYX, INC. (US) 2009-02-26 WO disclosed
WO-2009025793-A2 HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF SENOMYX, INC. (US) 2009-02-26 WO disclosed
US-20080009533-A1 SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS AND METHOD BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274632-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof TAS2R50, TAS2R1, TAS2R30 SLC2A4 1419/4885EGFR 607/4885CYP1A2 1626/4885
US-20100254916-A1 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof TAS2R50, TAS2R1, TAS2R30 SLC2A4 1453/4885EGFR 602/4885CYP1A2 1614/4885
US-20080009533-A1 SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS AND METHOD FABP4, LIPA, LIPC SLC2A4 305/4885EGFR 3076/4885CYP1A2 875/4885
US-20160376263-A1 BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF TAS2R5, TAS1R1, TAS2R1 SLC2A4 2776/4885EGFR 269/4885CYP1A2 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.